Ebola

Mary Choi, MD, MPH, discusses the progress made in treating and preventing Ebola and the challenges of fighting the community resistance of the Congolese.

The Contagion® editorial staff will be providing exclusive written and video coverage from ID Week 2018.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

Global health officials are concerned about the potential consequences of the disruption to Ebola surveillance in the DRC outbreak caused by civil unrest.

Ebola is not the only infectious disease that health officials in the Democratic Republic of the Congo are struggling with.

The National Emerging Infectious Disease Laboratories at Boston University have the latest equipment, security redundancies, and airtight procedures and protocols. Yet, as they begin work on Ebola and Marburg, they cannot eliminate the risk of human error.

The Democratic of the Congo Ministry of Health has authorized the use of 5 experimental Ebola treatments as more than 100 cases of Ebola are reported.

A 2-week old Ebola outbreak in the DRC has already surpassed the previous outbreak

New cases of Ebola were confirmed in the North Kivu Province, just 1 week after the outbreak in the Equator Province ended.

After 42 days without any new confirmed cases, the ninth Ebola outbreak in the Democratic Republic of the Congo is officially over.

Scientists supported by the NIAID discover a set of broadly neutralizing antibodies in the blood of Ebola survivors capable of providing substantial protection against the disease.

We're discussing presentations ranging from radiation biodosimetry to rapid viral testing

There have been no confirmed cases of Ebola in the Democratic Republic of the Congo since June 6.

An Ebola virus outbreak that began in the DRC in May has been the first in which a new vaccine and several therapeutic drugs have been available, and health officials around the world are praising the response.

The FDA seeks a permanent injunction against a company selling unapproved hand sanitizers that claim to be effective against infections from several pathogens.

Single-dose vaccines delivered via a new technology platform may offer full protection against Zika, Lassa fever, and Ebola.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

A new report by Global Health Technologies Coalition assesses the economic impact of cuts to global health R&D on the economies of US states.

A recent study has found that a single-dose of Merck's Ebola vaccine delivers antibodies that can last for 1 to 2 years.

The tech mogul shares that world leaders need to prepare for the next pandemic—whatever the root cause—including plans for mobilizing military, health, and other resources while coordinating efforts with private industry.

The US Centers for Disease Control and Prevention (CDC) has requested funds for a new high containment lab; let's give it to them.

The program can detect viral hemorrhagic fevers about 12 days faster than previous efforts.

The Global Virome Project is set to launch in 2018, and will spend the next 10 years working to identify as many as 827,000 unknown viruses in the wild.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.